Brief Report Claims Dexcom Marketed Defective G7 Device Noted by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Should l Buy ABT?
Source: Benzinga
DexCom's G7 Device Issues: A report by Hunterbrook Media highlights that DexCom's G7 glucose monitoring device was sold despite unauthorized design changes leading to accuracy issues, resulting in increased patient complaints and scrutiny from the FDA.
Patient Safety Concerns: Reports indicate severe consequences for patients, including hospitalizations and alleged deaths due to inaccurate readings from the G7, prompting many to revert to the previous G6 model or switch to competitors.
Corporate Culture and Accountability: Former employees criticized DexCom's culture for prioritizing profits over patient safety, with claims that the G7 was rushed to market and that leadership lacked necessary expertise.
Financial and Leadership Challenges: DexCom faces financial scrutiny over accounting practices and has experienced executive departures, including the CEO, amid rising competition from Abbott and other diabetes treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 102.380
Low
136.00
Averages
148.11
High
169.00
Current: 102.380
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High-Quality Healthcare Stocks
- HCA Healthcare's Market Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., leveraging strong community ties and relationships with third-party payers to maintain its leading position in a competitive healthcare industry, with a market cap of $106 billion.
- Stable Financial Performance: Over the past year, HCA Healthcare's stock has surged due to excellent financial results, with consistent revenue and earnings providing a solid foundation for future market share growth, despite facing legal and regulatory risks.
- Abbott's Innovation Capability: Abbott Laboratories offers innovative medical devices across several therapeutic areas, with its FreeStyle Libre continuous glucose monitoring system showing strong growth prospects globally, boasting a market cap of $178 billion and a gross margin of 52.72%.
- Ongoing Product Development: Abbott is expected to continue developing new products, and with its patent protections and strong reputation in the healthcare industry, it is poised for long-term financial growth, while its status as a Dividend King attracts long-term investors.
See More
Healthcare Stocks with Long-Term Return Potential
- HCA's Network Advantage: HCA Healthcare operates a diversified network of facilities across the U.S., leveraging strong relationships with government and third-party payers to maintain a competitive edge, which is expected to benefit from the aging population and drive long-term revenue growth.
- Stable Financial Performance: Over the past year, HCA's stock surged due to excellent financial results, and its ongoing market share growth strategy, along with investments in cutting-edge technology, will further solidify its market position despite facing legal and regulatory risks.
- Abbott's Innovative Product Line: Abbott Laboratories offers leading medical devices across several therapeutic areas, particularly its FreeStyle Libre continuous glucose monitoring system, which is poised for growth due to low global penetration, enhancing the company's financial performance.
- Dividend King Status: Abbott is recognized as a Dividend King, having increased dividends for 50 consecutive years, showcasing its strong profitability and stable cash flow, making it an ideal choice for long-term investors.
See More
Whoop Secures $575 Million in Series G Funding
- Significant Funding Round: Whoop raised $575 million in its latest Series G funding, achieving a valuation of $10.1 billion, which underscores its strong appeal in the wearable device market and investor confidence.
- Strong Investor Lineup: The funding round was led by Collaborative Fund and included participation from prominent institutions like Qatar Investment Authority and Mubadala Investment Company, along with sports stars such as Cristiano Ronaldo and LeBron James, enhancing brand visibility.
- Rapid Business Growth: Whoop currently boasts 2.5 million members, with bookings growing 103% year-over-year, and exited 2025 with a bookings run rate of $1.1 billion, indicating the success of its business model and robust market demand.
- Leading Technological Innovations: The newly launched Whoop MG model received FDA clearance for medical-grade ECG and blood pressure monitoring, marking a significant shift towards clinical health integration, while continuing to leverage AI for personalized training recommendations, enhancing user experience.
See More
Abbott Integrates Precision Oncology Solutions with Flatiron Health
- Precision Oncology Integration: Abbott and Flatiron Health announced the integration of Abbott's Precision Oncology portfolio into the OncoEMR platform, enabling oncology providers to digitally order Abbott tests within their existing clinical workflows, enhancing treatment decision efficiency.
- Increased Test Accessibility: This integration allows access to Abbott's Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard tests across Flatiron's network of over 1,600 community cancer care centers, covering 4,700 providers and significantly improving patient access to testing.
- Administrative Burden Reduction: The integration enables clinicians to receive status updates and results directly within OncoEMR, thereby reducing administrative burdens and allowing healthcare professionals to focus more on patient care, ultimately enhancing the quality of healthcare services.
- Accelerated Treatment Decisions: The collaboration between Abbott and Flatiron aims to remove key barriers in community oncology practices, accelerating treatment decision-making processes and facilitating personalized patient care, aligning with the modern healthcare demand for data-driven solutions.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
Schwab U.S. Dividend ETF Reconstitutes, Increases Healthcare Holdings
- Healthcare Stock Increase: The Schwab U.S. Dividend ETF's recent annual reconstitution added two healthcare stocks, raising the sector's allocation from 15.4% to 18.9%, making it the second-largest sector, indicating a strategic focus on the growth potential of healthcare.
- High-Yield Stock Selection: During this reconstitution, UnitedHealth and Abbott Laboratories were added to the top ten holdings with allocations of 4% and 3.95%, respectively, reflecting the fund's preference for high-yield healthcare stocks, which is expected to enhance long-term investor returns.
- Dividend Growth Potential: The new holdings have an average dividend growth rate of 9.4%, surpassing the pre-reconstitution rate of 8.6%, and while the overall yield remains at 3.4%, the faster growth rate could lead to higher total returns for investors in the future.
- Strong Dividend Records: Both UnitedHealth and Abbott have robust dividend growth histories, with the former increasing its dividend by 52% over the past five years and the latter by 40%, showcasing the attractiveness and stability of the healthcare sector in dividend investing.
See More
Analysis of High-Quality Healthcare Stocks
- HCA Healthcare's Market Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., leveraging strong community ties and relationships with third-party payers to maintain its leading position in a competitive healthcare industry, with a market cap of $106 billion.
- Stable Financial Performance: Over the past year, HCA Healthcare's stock has surged due to excellent financial results, with consistent revenue and earnings providing a solid foundation for future market share growth, despite facing legal and regulatory risks.
- Abbott's Innovation Capability: Abbott Laboratories offers innovative medical devices across several therapeutic areas, with its FreeStyle Libre continuous glucose monitoring system showing strong growth prospects globally, boasting a market cap of $178 billion and a gross margin of 52.72%.
- Ongoing Product Development: Abbott is expected to continue developing new products, and with its patent protections and strong reputation in the healthcare industry, it is poised for long-term financial growth, while its status as a Dividend King attracts long-term investors.
See More
Healthcare Stocks with Long-Term Return Potential
- HCA's Network Advantage: HCA Healthcare operates a diversified network of facilities across the U.S., leveraging strong relationships with government and third-party payers to maintain a competitive edge, which is expected to benefit from the aging population and drive long-term revenue growth.
- Stable Financial Performance: Over the past year, HCA's stock surged due to excellent financial results, and its ongoing market share growth strategy, along with investments in cutting-edge technology, will further solidify its market position despite facing legal and regulatory risks.
- Abbott's Innovative Product Line: Abbott Laboratories offers leading medical devices across several therapeutic areas, particularly its FreeStyle Libre continuous glucose monitoring system, which is poised for growth due to low global penetration, enhancing the company's financial performance.
- Dividend King Status: Abbott is recognized as a Dividend King, having increased dividends for 50 consecutive years, showcasing its strong profitability and stable cash flow, making it an ideal choice for long-term investors.
See More
Whoop Secures $575 Million in Series G Funding
- Significant Funding Round: Whoop raised $575 million in its latest Series G funding, achieving a valuation of $10.1 billion, which underscores its strong appeal in the wearable device market and investor confidence.
- Strong Investor Lineup: The funding round was led by Collaborative Fund and included participation from prominent institutions like Qatar Investment Authority and Mubadala Investment Company, along with sports stars such as Cristiano Ronaldo and LeBron James, enhancing brand visibility.
- Rapid Business Growth: Whoop currently boasts 2.5 million members, with bookings growing 103% year-over-year, and exited 2025 with a bookings run rate of $1.1 billion, indicating the success of its business model and robust market demand.
- Leading Technological Innovations: The newly launched Whoop MG model received FDA clearance for medical-grade ECG and blood pressure monitoring, marking a significant shift towards clinical health integration, while continuing to leverage AI for personalized training recommendations, enhancing user experience.
See More
Abbott Integrates Precision Oncology Solutions with Flatiron Health
- Precision Oncology Integration: Abbott and Flatiron Health announced the integration of Abbott's Precision Oncology portfolio into the OncoEMR platform, enabling oncology providers to digitally order Abbott tests within their existing clinical workflows, enhancing treatment decision efficiency.
- Increased Test Accessibility: This integration allows access to Abbott's Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard tests across Flatiron's network of over 1,600 community cancer care centers, covering 4,700 providers and significantly improving patient access to testing.
- Administrative Burden Reduction: The integration enables clinicians to receive status updates and results directly within OncoEMR, thereby reducing administrative burdens and allowing healthcare professionals to focus more on patient care, ultimately enhancing the quality of healthcare services.
- Accelerated Treatment Decisions: The collaboration between Abbott and Flatiron aims to remove key barriers in community oncology practices, accelerating treatment decision-making processes and facilitating personalized patient care, aligning with the modern healthcare demand for data-driven solutions.
See More
Schwab U.S. Dividend Equity ETF Reconstitution Boosts Healthcare Allocation
- Annual Reconstitution Update: The Schwab U.S. Dividend Equity ETF has optimized its portfolio through the deletion of 22 stocks and the addition of 25 new stocks in its latest annual reconstitution, ensuring it holds the top 100 high-yield dividend stocks and enhancing overall portfolio quality.
- Increased Healthcare Allocation: Following the reconstitution, the allocation to the healthcare sector has risen from 15.4% to 18.9%, with UnitedHealth and Abbott Laboratories joining the top ten holdings at 4% and 3.95% respectively, thereby strengthening the fund's investment in the healthcare sector.
- Dividend Growth Potential: While the overall dividend yield of the ETF remains at 3.4% post-reconstitution, the new holdings boast a higher average five-year dividend growth rate of 9.4%, which is expected to generate greater long-term income for investors, enhancing the fund's appeal.
- Strong Dividend Track Record: Both UnitedHealth and Abbott Laboratories have impressive dividend growth records, with the former increasing dividends by 52% over the past five years and the latter by 40%, providing investors with a stable income source and further solidifying the ETF's investment value.
See More
Schwab U.S. Dividend ETF Reconstitutes, Increases Healthcare Holdings
- Healthcare Stock Increase: The Schwab U.S. Dividend ETF's recent annual reconstitution added two healthcare stocks, raising the sector's allocation from 15.4% to 18.9%, making it the second-largest sector, indicating a strategic focus on the growth potential of healthcare.
- High-Yield Stock Selection: During this reconstitution, UnitedHealth and Abbott Laboratories were added to the top ten holdings with allocations of 4% and 3.95%, respectively, reflecting the fund's preference for high-yield healthcare stocks, which is expected to enhance long-term investor returns.
- Dividend Growth Potential: The new holdings have an average dividend growth rate of 9.4%, surpassing the pre-reconstitution rate of 8.6%, and while the overall yield remains at 3.4%, the faster growth rate could lead to higher total returns for investors in the future.
- Strong Dividend Records: Both UnitedHealth and Abbott have robust dividend growth histories, with the former increasing its dividend by 52% over the past five years and the latter by 40%, showcasing the attractiveness and stability of the healthcare sector in dividend investing.
See More
